Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07007780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 29, 2025 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 20, 2025 to Aug 20, 2025v2 Show 6 more changesShow less
    • Primary completion date: Jul 31, 2026 to Aug 31, 2026
    • Study completion date: Jun 30, 2027 to Aug 30, 2027
    • Interventions: Lutikizumab monotherapy (Drug) to Sacituzumab Tirumotecan (Drug)
    • Secondary endpoints: 2 to 3
    • Study description shortened, about 42 words
    • Study title expanded, about 1 word
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To explore the application of Sacituzumab Tirumotecan in neoadjuvant treatment of early-stage TNBC, a multicenter, Phase II clinical study of Sacituzumab Tirumotecan in neoadjuvant treatment of early-stage TNBC is proposed. The study aims to evaluate the efficacy and safety of Sacituzumab Tirumotecan and to provide a new treatment option for neoadjuvant treatment of early-stage TNBC.
Trial Details
NCT Number NCT07007780
Lead Sponsor Xijing Hospital
Conditions
(from sponsor)		 Triple -Negative Breast Cancer
Related terms Triple Negative Breast Neoplasms
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov